Septerna Announces Closing Of $331.2 Million Upsized Initial Public Offering

( MENAFN - GlobeNewsWire - Nasdaq) SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc.

(Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.

The aggregate gross proceeds to Septerna from the IPO were $331.2 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Market on October 25, 2024, under the ticker symbol“SEPN.

” J.P. Morgan, TD Cowen, Cantor and Wells Fargo Securities acted as joint bookrunners for the offering.

A registration statement relating to the shares sold in the initial public offering has been filed with the Securities and Exchange Commission and was declared effective on October 24, 2024. The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: J.

P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by email at ..

. and ..

.; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by teleph.